ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Neorutin® 300:Helvepharm AG
Information professionnelle complèteDDDimprimé 
Forme gal./Grpe.th.Composit.PropriétésPharm.cinét.Indic./emploiPosolog./mode d'empl.PrécautionsEffets indésir.
Interact.RemarquesNum. SwissmedicMise à jour 
C05CA01 - RutosideATC-DDD Version 2016. Source: WHO
C - Cardiovascular System

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.

C05 - Vasoprotectives
 

No DDDs are established in this group, since most of the drugs in this group are for topical use.

C05C - Capillary Stabilizing Agents
 
C05CA - Bioflavonoids

Rutoside is classified in this group.
Oxerutines are classified in C05CA54.
Combinations with other capillary stabilizing agents are classified at separate 5th levels using the corresponding 50-series.

C05CA01 - Rutoside
2024 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home